|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baselga J and Swain SM: Novel anticancer
targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sliwkowski MX, Lofgren JA, Lewis GD,
Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing
the mechanism of action of trastuzumab (Herceptin). Semin Oncol.
26:60–70. 1999.PubMed/NCBI
|
|
5
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nahta R and Esteva FJ: Herceptin:
mechanisms of action and resistance. Cancer Lett. 232:123–138.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hudis CA: Trastuzumab - mechanism of
action and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nahta R and Esteva FJ: Trastuzumab:
triumphs and tribulations. Oncogene. 26:3637–3643. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valabrega G, Montemurro F and Aglietta M:
Trastuzumab: mechanism of action, resistance and future
perspectives in HER2-overexpressing breast cancer. Ann Oncol.
18:977–984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L and Hannon GJ: MicroRNAs: small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oneyama C, Morii E, Okuzaki D, et al:
MicroRNA-mediated upregulation of integrin-linked kinase promotes
Src-induced tumor progression. Oncogene. 31:1623–1635. 2012.
View Article : Google Scholar
|
|
13
|
Yoon S, Choi YC, Lee S, Jeong Y, Yoon J
and Baek K: Induction of growth arrest by miR-542-3p that targets
survivin. FEBS Lett. 584:4048–4052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He T, Qi F, Jia L, et al: MicroRNA-542-3p
inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol.
232:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee S, Yang W, Lan KH, et al: Enhanced
sensitization to taxol-induced apoptosis by herceptin pretreatment
in ErbB2- overexpressing breast cancer cells. Cancer Res.
62:5703–5710. 2002.PubMed/NCBI
|
|
16
|
Baselga J, Norton L, Albanell J, Kim YM
and Mendelsohn J: Recombinant humanized anti-HER2 antibody
(Herceptin) enhances the antitumor activity of paclitaxel and
doxorubicin against HER2/neu overexpressing human breast cancer
xenografts. Cancer Res. 58:2825–2831. 1998.PubMed/NCBI
|
|
17
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Shang X, Sarkissyan M, Slamon D and
Vadgama JV: FOXO1A is a target for HER2-overexpressing breast
tumors. Cancer Res. 70:5475–5485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sumikawa T, Shigeoka Y, Igishi T, et al:
Dexamethasone interferes with trastuzumab-induced cell growth
inhibition through restoration of AKT activity in BT-474 breast
cancer cells. Int J Oncol. 32:683–688. 2008.PubMed/NCBI
|
|
21
|
Grell P, Fabian P, Khoylou M, et al: Akt
expression and compartmentalization in prediction of clinical
outcome in HER2-positive metastatic breast cancer patients treated
with trastuzumab. Int J Oncol. 41:1204–1212. 2012.PubMed/NCBI
|
|
22
|
Chung SS, Giehl N, Wu Y and Vadgama JV:
STAT3 activation in HER2-overexpressing breast cancer promotes
epithelial-mesenchymal transition and cancer stem cell traits. Int
J Oncol. 44:403–411. 2014.
|
|
23
|
Davis R, Singh KP, Kurzrock R and Shankar
S: Sulforaphane inhibits angiogenesis through activation of FOXO
transcription factors. Oncol Rep. 22:1473–1478. 2009.PubMed/NCBI
|
|
24
|
Han J, Pan XY, Xu Y, et al: Curcumin
induces autophagy to protect vascular endothelial cell survival
from oxidative stress damage. Autophagy. 8:812–825. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou J, Liao W, Yang J, et al: FOXO3
induces FOXO1-dependent autophagy by activating the AKT1 signaling
pathway. Autophagy. 8:1712–1723. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chakrabarty A, Bhola NE, Sutton C, et al:
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis
and are sensitive to PI3K inhibitors. Cancer Res. 73:1190–1200.
2013. View Article : Google Scholar :
|
|
27
|
Engelman JA: Targeting PI3K signalling in
cancer: opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fruman DA and Rommel C: PI3K and cancer:
lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
